Skip to main content

Table 1 Patient demographics

From: Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer

Parameter

Non-continuous dosing (n = 11)

Continuous dosing (n = 28)

Total (n = 39)

Gender (female/male)

5 (45%)/6 (55%)

14 (50%)/14 (50%)

19 (49%)/20 (51%)

Mean age (range) (years)

62.4 (42-80)

59.4 (22-78)

60.2 (22-80)

Mean BMI (range) (kg/m2)

26.5 (21.9-32.0)

26.0 (18.2-37.4)

26.2 (18.2-37.4)

ECOG PS (0/1)

7 (64%)/4 (36%)

23 (82%)/5 (18%)

30 (77%)/9 (23%)

Prior chemotherapy

10 (91%)

28 (100%)

38 (97%)

Prior radiotherapy

3 (27%)

8 (29%)

11 (28%)

Prior surgery

11 (100%)

27 (96%)

38 (97%)

  1. - BMI - body mass index
  2. - ECOG PS - Eastern Cooperative Oncology Group performance status.